- Title: Subtitle
- Baseline Characteristics of Patients With Fabry Disease Enrolled in the Pegunigalsidase Alfa Expanded-Access Program: FR-PO339
- Creators
- Ankit Mehta - Baylor University Medical CenterWilliam Wilcox - Emory UniversityKhan J. Nedd - Infusion AssociatesJohn A. Bernat - University of IowaJasmine Knoll - Phoenix Children's HospitalJohn L. Jefferies - University of Tennessee Health Science CenterNicola Longo - University of UtahEric L. Wallace - University of Alabama at BirminghamEinat Almon - Protalix BioTherapeuticsSari Alon - Protalix BioTherapeuticsRaul Chertkoff - Protalix BioTherapeuticsDawn Sullivan - Chiesi USA, Inc, Boston, MARossana Rocco - ChiesiIrene Koulinska - ChiesiOzlem Goker-Alpan - Lysosomal and Rare Disorders Research and Treatment Center
- Resource Type
- Abstract
- Publication Details
- Journal of the American Society of Nephrology, Vol.33(11S), pp.417-417
- DOI
- 10.1681/ASN.20223311S1417a
- ISSN
- 1046-6673
- eISSN
- 1533-3450
- Language
- English
- Date published
- 11/2022
- Academic Unit
- Stead Family Department of Pediatrics; Medical Genetics and Genomics
- Record Identifier
- 9984648576402771
Abstract
Baseline Characteristics of Patients With Fabry Disease Enrolled in the Pegunigalsidase Alfa Expanded-Access Program: FR-PO339
Journal of the American Society of Nephrology, Vol.33(11S), pp.417-417
11/2022
DOI: 10.1681/ASN.20223311S1417a
Details
Metrics
7 Record Views